Overview

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.
Phase:
PHASE1
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
entacapone